Adenomatous Polyposis Coli
Conditions
Keywords
Familial Adenomatous Polyposis, Attenuated Familial Polyposis
Brief summary
The purpose of this study is to determine in a randomized, placebo-controlled, phase II trial if the combination of sulindac and erlotinib causes a significant regression of duodenal and colorectal adenomas in familial adenomatous polyposis (FAP) and attenuated FAP (AFAP) patients.
Detailed description
This will be a single-center, phase-II, six-month-long, placebo-controlled, double blinded, randomized trial of the epidermal growth factor receptor (EGFR) inhibitor, erlotinib (Tarceva) and the cyclooxygenase (COX-2) inhibitor, sulindac in patients with familial adenomatous polyposis (FAP) or attenuated FAP. FAP is an autosomal dominant inherited colon cancer predisposition with a 100% risk of colon cancer in the absence of preventive care (endoscopy and surgery). Efficacious chemoprevention for duodenal adenomas is an unmet clinical need in FAP patients that would reduce the morbidity from duodenectomy and risk of duodenal adenocarcinoma. Currently the only Food and Drug Administration (FDA)-approved chemopreventive agent is celecoxib which results in a modest reduction of duodenal and colorectal polyps and is associated with cardiac toxicity at effective doses. If it can be shown that combinatorial inhibition of COX-2 and EGFR activity leads to successful regression in duodenal adenomatous polyps in FAP, it could be used as an effective chemopreventive regimen in FAP patients with duodenal adenomas or who have undergone surgical resection of duodenal adenomas or have many rectal adenomas. FAP and AFAP patients will be screened by endoscopy for presence of 5 or more duodenal polyps, then randomized to either A) erlotinib at 75 mg/day and sulindac at 150 mg/day or B) placebo for 6 months. The endpoint will be endoscopy at 6 months. Primary Aim : To determine if the combination of sulindac and erlotinib causes a significant regression of duodenal polyp burden at 6 mohths in FAP and attenuated FAP patients. Secondary Aim: To measure if combination of sulindac and erlotinib cause a reduction in total duodenal polyp count, and change in duodenal polyp burden or count stratified by genotype and initial polyp burden.
Interventions
DRUGErlotinib
Tarceva oral tablets are conventional, immediate-release tablets containing erlotinib as the hydrochloride salt. Erlotinib(75mg)will be taken once daily for six months in combination with sulindac.
DRUGSulindac
Sulindac is a non-steroidal, anti-inflammatory indene derivative designed for the treatment of arthritic conditions. For this study, sulindac (150mg) will be taken twice daily in combination with erlotinib
DRUGPlacebo A
Erlotinib (Tarceva) will provide a 25 mg identical placebo. This will be provided by the Division of Cancer Prevention at the NIH who will receive the drug and placebo from the manufacturer, OSI/Genentech. Dosage for Placebo A will be 75 mg a day for 6 months.
DRUGPlacebo B
Sulindac will be encapsulated in 150 mg doses along with an identical encapsulated Placebo B. One 150 mg capsules of Placebo B will be taken twice per day with meals (breakfast and supper).
Sponsors
National Cancer Institute (NCI)
University of Utah
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 69 Years
Healthy volunteers
No
Inclusion criteria
* Patients who are 18 years or older with a clinical or genetic diagnosis of FAP or attenuated FAP. * Presence of duodenal polyps with a sum of diameters ≥ 5mm. * Minimum of two weeks since any major surgery * WHO performance status ≤1 * Adequate bone marrow function as show by: normal leukocyte count, platelet count ≥ 120 x 109/L, Hgb \> 12 g/dL * Adequate liver function as shown by: normal serum bilirubin(≤ 1.5 Upper Limit Normal {ULN}) and serum transaminases (≤ 2.0 ULN) * Patient must discontinue taking any Nonsteroidal anti-inflammatory drugs (NSAIDS) within one month of treatment initiation. * Patients must be able to provide written informed consent.
Exclusion criteria
* Prior treatment with any investigational drug within the preceding 4 weeks. * Malignancies within the past 3 years except for adequately treated carcinoma of the cervix or basal or squamous cell carcinomas of the skins. * Patients who have any severe and/or uncontrolled medical conditions or other conditions that could affect their participation in the study as determined by the Principal Investigator such as: 1. Unstable angina pectoris, symptomatic congestive heart failure, myocardial infarction ≤ 6 months prior to first study treatment, serious uncontrolled cardiac arrhythmia 2. Severely impaired lung function 3. Any active (acute or chronic) or uncontrolled infection/ disorders. 4. Nonmalignant medical illnesses that are uncontrolled or whose control may be jeopardized by the treatment with the study therapy 5. Liver disease such as cirrhosis, chronic active hepatitis or chronic persistent hepatitis * Screening clinical laboratory values that indicate any of the following: 1. anemia 2. thrombocytopenia 3. leucopenia 4. elevations of transaminases greater than 2X ULN 5. elevation of bilirubin \> 1.5 X ULN 6. alkaline phosphatase elevation \> 1.5 X ULN 7. increased creatinine, urinary protein, or urinary casts outside the clinically normal range. * Gastrointestinal bleeding (symptoms including dyspnea, fatigue, angina, weakness, malaise, melena, hematochezia, hematemesis, anemia or abdominal pain will require clinical assessment to rule out gastrointestinal bleeding). * Patient who is currently taking any anti-coagulation medication. * Women who are pregnant or breast feeding. * Patients with a known hypersensitivity to sulindac or erlotinib or to their excipients
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Duodenal Polyp Burden From Baseline to 6 Months | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arms of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). |
| Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden). |
| Change in Number of Duodenal Polyps From Baseline to 6 Months | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arms of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count). |
| Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count) |
| Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants | Baseline and 6 months | A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count) |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Sulindac-erlotinib Sulindac 150 mg twice daily in combination with erlotinib 75 mg per day for 6 months | 46 |
| Placebo Placebo capsules matching erlotinib active comparator (Placebo A) once daily and placebo capsules matching sulindac active comparator (Placebo B) twice daily for 6 months | 46 |
| Total | 92 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 |
|---|---|---|---|
| Overall Study | Adverse Event | 3 | 0 |
| Overall Study | Lost to Follow-up | 1 | 2 |
| Overall Study | No Endpoint due to Early Study Halt | 2 | 3 |
| Overall Study | Pregnancy | 0 | 2 |
| Overall Study | Protocol Violation | 1 | 0 |
| Overall Study | Suspected Allergic Reaction | 1 | 1 |
| Overall Study | Unrelated Health Reasons | 1 | 2 |
Baseline characteristics
| Characteristic | Sulindac-erlotinib | Placebo | Total |
|---|---|---|---|
| Age, Continuous | 42 years STANDARD_DEVIATION 14 | 41 years STANDARD_DEVIATION 14 | 41 years STANDARD_DEVIATION 14 |
| Familial Adenomatous Polyposis (FAP) Status Attenuated FAP | 14 participants | 14 participants | 28 participants |
| Familial Adenomatous Polyposis (FAP) Status Classic FAP | 32 participants | 32 participants | 64 participants |
| Sex: Female, Male Female | 28 Participants | 28 Participants | 56 Participants |
| Sex: Female, Male Male | 18 Participants | 18 Participants | 36 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk |
|---|---|---|
| deaths Total, all-cause mortality | — / — | — / — |
| other Total, other adverse events | 43 / 46 | 33 / 46 |
| serious Total, serious adverse events | 0 / 46 | 0 / 46 |
Outcome results
Primary
Change in Duodenal Polyp Burden From Baseline to 6 Months
A comparison between the Sulindac-erlotinib and Placebo arms of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Duodenal Polyp Burden From Baseline to 6 Months | -8.5 mm |
| Placebo | Change in Duodenal Polyp Burden From Baseline to 6 Months | 8.0 mm |
p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary
Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants
A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
Time frame: Baseline and 6 months
Population: Attenuated FAP participants are defined with the presence of a mutation in a portion of the adenomatous polyposis coli (APC) gene known to correlate with attenuated FAP and presentation of a milder phenotype in terms of polyp density in the participant and the family. All participants with attenuated FAP had a confirmed mutation in the APC gene.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants | -8.0 mm |
| Placebo | Change in Duodenal Polyp Burden From Baseline to 6 Months in Attenuated FAP Participants | 7.0 mm |
p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary
Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants
A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in polyp burden from a 10-centimeter segment of the duodenum, measured as the sum of the diameters of the polyps, in millimeters (mm), from the duodenal segment (6-month polyp burden minus baseline polyp burden).
Time frame: Baseline and 6 months
Population: Classic FAP participants are defined as those presenting with more than 100 colonic adenomas and either (1) multiple family members with a classic FAP phenotype or (2) an adenomatous polyposis coli (APC) mutation in a region of the gene known to correlate with Classic FAP, or (3) both.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants | -8.5 mm |
| Placebo | Change in Duodenal Polyp Burden From Baseline to 6 Months in Classic Familial Adenomatous Polyposis (FAP) Participants | 8.5 mm |
p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary
Change in Number of Duodenal Polyps From Baseline to 6 Months
A comparison between the Sulindac-erlotinib and Placebo arms of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count).
Time frame: Baseline and 6 months
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Number of Duodenal Polyps From Baseline to 6 Months | -2.8 polyps |
| Placebo | Change in Number of Duodenal Polyps From Baseline to 6 Months | 4.3 polyps |
p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary
Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants
A comparison between the Sulindac-erlotinib and Placebo arm Attenuated FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count)
Time frame: Baseline and 6 months
Population: Attenuated FAP participants are defined with the presence of a mutation in a portion of the adenomatous polyposis coli (APC) gene known to correlate with attenuated FAP and presentation of a milder phenotype in terms of polyp density in the participant and the family. All participants with attenuated FAP had a confirmed mutation in the APC gene.
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants | -4.3 polyps |
| Placebo | Change in Number of Duodenal Polyps From Baseline to 6 Months in Attenuated FAP Participants | 4.9 polyps |
p-value: <0.001Wilcoxon (Mann-Whitney)
Secondary
Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants
A comparison between the Sulindac-erlotinib and Placebo arm Classic FAP subgroups of the change in number of polyps in a 10-centimeter segment of the duodenum (6-month polyp count minus baseline polyp count)
Time frame: Baseline and 6 months
Population: Classic FAP participants are defined as those presenting with more than 100 colonic adenomas and either (1) multiple family members with a classic FAP phenotype or (2) an adenomatous polyposis coli (APC) mutation in a region of the gene known to correlate with Classic FAP, or (3) both
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Sulindac-erlotinib | Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants | -2.1 polyps |
| Placebo | Change in Number of Duodenal Polyps From Baseline to 6 Months in Classic FAP Participants | 4.0 polyps |
p-value: <0.001Wilcoxon (Mann-Whitney)